Venus Medtech (Hangzhou) Inc.
2500.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$482.91M
Close$
Share Statistics
| Market cap | $482.91 Million |
|---|---|
| Enterprise Value | $599.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 1.11 |
| Outstanding Shares | 437,897,443 |
Return
| Return on Equity | -72.23% |
|---|---|
| Return on Assets | -49.57% |
| Return on Invested Capital | -55.25% |
Valuation & Multiples
| P/E Ratio | -0.88 |
|---|---|
| PEG | -2.1 |
| Price to Sales | 1.1 |
| Price to Book Ratio | 0.37 |
| Enterprise Value to Revenue | 0.88 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$156.67 M
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$152.63 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Venus Medtech (Hangzhou) Inc.
557 employees
CEO: Hou-Sen Lim Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic h...